Chugai Pharmaceutical Quick Ratio 2020-2025 | CHGCY

Chugai Pharmaceutical quick ratio for the quarter ending March 31, 2025 was 6.16.

  • Chugai Pharmaceutical average quick ratio for 2024 was 4.59, a 52.49% increase from 2023.
  • Chugai Pharmaceutical average quick ratio for 2023 was 3.01, a 11.48% increase from 2022.
  • Chugai Pharmaceutical average quick ratio for 2022 was 2.7, a 30.05% increase from 2021.

Quick ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated by subtracting inventory from current assets and dividing by current liabilities.

Chugai Pharmaceutical Quick Ratio 2020-2025 | CHGCY

  • Chugai Pharmaceutical average quick ratio for 2024 was 4.59, a 52.49% increase from 2023.
  • Chugai Pharmaceutical average quick ratio for 2023 was 3.01, a 11.48% increase from 2022.
  • Chugai Pharmaceutical average quick ratio for 2022 was 2.7, a 30.05% increase from 2021.

Quick ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated by subtracting inventory from current assets and dividing by current liabilities.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$67.1B
Daiichi Sankyo, - (DSNKY)$46.4B
Takeda Pharmaceutical (TAK)$45.5B
BeOne Medicines - (ONC)$32.3B
Sandoz Group AG (SDZNY)$26.1B
Summit Therapeutics (SMMT)$20.4B
Merck (MKKGY)$16.9B
Shionogi (SGIOY)$15B
United Therapeutics (UTHR)$13.4B
Neurocrine Biosciences (NBIX)$13.2B
Orion OYJ (ORINY)$11.5B
IPSEN (IPSEY)$10.8B
Stevanato Group S.p.A (STVN)$7.9B
Corcept Therapeutics (CORT)$7.3B
Grifols, S.A (GRFS)$6.9B
Ionis Pharmaceuticals (IONS)$6.6B
Madrigal Pharmaceuticals (MDGL)$6.5B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.3B
Hypermarcas (HYPMY)$3B
Crinetics Pharmaceuticals (CRNX)$2.8B
NewAmsterdam Pharma (NAMS)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2B
Ocular Therapeutix (OCUL)$1.9B
Endo (NDOI)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.7B